The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy

Lilla Hornyák, Nikoletta Dobos, G. Koncz, Z. Karányi, D. Páll, Z. Szabó, Gábor Halmos, Lóránt Székvölgyi

Research output: Contribution to journalShort survey

57 Citations (Scopus)


Tumors are composed of abnormally transformed cell types and tissues that differ from normal tissues in their genetic and epigenetic makeup, metabolism, and immunology. Molecular compounds that modulate the immune response against neoplasms offer promising new strategies to combat cancer. Inhibitors targeting the indoleamine-2,3-dioxygenase 1 enzyme (IDO1) represent one of the most potent therapeutic opportunities to inhibit tumor growth. Herein, we assess the biochemical role of IDO1 in tumor metabolism and immune surveillance, and review current diagnostic and therapeutic approaches that are intended to increase the effectiveness of immunotherapies against highly aggressive and difficult-to-treat IDO-expressing cancers.

Original languageEnglish
Article number151
JournalFrontiers in Immunology
Issue numberJAN
Publication statusPublished - Jan 31 2018



  • Cancer diagnostics
  • Clinical trial
  • Gene expression
  • Immune surveillance
  • Immunotherapy
  • Indoleamine-2,3-dioxygenase
  • Metabolism

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this